AusPAR: Durvalumab

Australian Public Assessment Report

AusPAR

AusPAR: Durvalumab [PDF, 593.11 KB]

AusPAR: Durvalumab [Word, 594.58 KB]

Attachment 1: Product Information for Durvalumab [PDF, 498.93 KB]

Attachment 1: Product Information for Durvalumab [Word, 508.18 KB]

Device/Product Name

Imfinzi

Active ingredients

Durvalumab

AusPAR Date

22 March 2021

Published

20 May 2021

Submission Number

PM-2019-04661-1-4

Submission Type

Extension of indications

Decision

Approved